Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses ZUMA-1 trial long term follow up and very few long term safety signals at the 2017 American Society of Hematology.
ZUMA-1 Trial Long Term Follow Up – Very Few Long Term Safety Signals
Advertisement
[the_ad id="32629"]